BRG1 inactivating mutations, with a corresponding loss of protein, have been identified in a variety of cell lines and primary tumours, such as pancreatic, breast and prostate cancer cell lines and in lung cancer and medulloblastoma10. This evidence concerns the gene SMARCA4 and Familial prostate cancer.